Novartis (NVS) Expected to Announce Quarterly Earnings on Friday

Novartis (NYSE:NVS) is expected to post its quarterly earnings results before the market opens on Friday, January 31st. Analysts expect Novartis to post earnings of $1.80 per share and revenue of $12.86 billion for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. The company had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period in the prior year, the firm posted $1.74 EPS. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Stock Up 1.2 %

Shares of Novartis stock opened at $103.09 on Thursday. The company has a 50-day simple moving average of $100.07 and a two-hundred day simple moving average of $108.57. Novartis has a 52-week low of $92.35 and a 52-week high of $120.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The stock has a market capitalization of $210.72 billion, a PE ratio of 11.97, a price-to-earnings-growth ratio of 1.42 and a beta of 0.57.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NVS shares. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. BMO Capital Markets upped their price target on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Finally, HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating and six have issued a hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.